Efficacy and Outcomes of CYP3A5 Genotype-Based Tacrolimus Dosing Compared to Conventional Body Weight-based Dosing in Living Donor Kidney Transplant Recipients

INTRODUCTION: Clinical use of tacrolimus has been challenging due to its narrow therapeutic index and highly variable pharmacokinetics. In this study, we compared patients who received body weight-based tacrolimus dosing pre-transplant (transplanted from 2016 to 2018) with those who received CYP3A5...

Descripción completa

Detalles Bibliográficos
Autores principales: Raj, T. Yashwanth, Fernando, M. Edwin, Srinivasa Prasad, N. D., Sujit, S., Valavan, K. Thirumal, Harshavardhan, T. S., Ramanathan, Arvind
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267083/
https://www.ncbi.nlm.nih.gov/pubmed/35814319
http://dx.doi.org/10.4103/ijn.IJN_278_20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267083/
https://www.ncbi.nlm.nih.gov/pubmed/35814319
http://dx.doi.org/10.4103/ijn.IJN_278_20

Ejemplares similares